ERBB2 and breast carcinoma: In conjunction with various other clinicopathological risk factors predictive of recurrence, the inclusion of the genomic assay Oncotype DX RS can provide additional confidence to healthcare providers when making decisions about adjuvant chemotherapy for HR+ HER2-negative breast cancer patients.